Philippe Guedat | Chief Executive Officer
InFlectis BioScience

Philippe Guedat, Chief Executive Officer, InFlectis BioScience

Phillippe Guedat
CEO / CSO, InFlectis BioScience

Philippe GUEDAT, PhD, InFlectis BioScience CEO/CSO (Founder), has 20 years of drug discovery experience having led drug discovery department at Vivalis (now Valneva, Nantes, France), where he developed anti-HCV molecules and industrialize a protein-protein interaction high throughput screening technology. Prior to Vivalis, he was director of chemistry at Hybrigenics (Paris, France), focusing the company’s interest on protein-protein interaction and the discovery of the first ubiquitin-specific protease inhibitors in oncology. Philippe is a graduate of Louis Pasteur University in Strasbourg where he received his PhD under the supervision of Prof. C-G Wermuth. He started his career in 1998 as a Research Assistant at Cambridge University and SmithKline Beecham (Harlow, UK) before joining Merck KGaA as medicinal chemist and discovery project leader working on the dyslipidemia field. He is a named inventor on 21 patents families and co-author of 17 publications. He discovered IFB-088 and demonstrated its activity on several neurodegenerative disease animal models through its action on UPR


World Orphan Drug Congress USA 2018 - Conference Day One @ 15:10

IFB-088 a potential new therapeutic option to treat demyelinating charcot-marie-tooth diseases

back to speakers